Rossari Biotech Crescita futura

Future criteri di controllo 4/6

Rossari Biotech prevede che gli utili e i ricavi cresceranno rispettivamente di 22.3% e 16.6% all'anno. Si prevede che l'EPS crescerà di 22.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 15.4% in 3 anni.

Informazioni chiave

22.3%

Tasso di crescita degli utili

22.3%

Tasso di crescita dell'EPS

Chemicals crescita degli utili	22.8%
Tasso di crescita dei ricavi	16.6%
Rendimento futuro del capitale proprio	15.4%
Copertura analitica	Low
Ultimo aggiornamento	23 Oct 2024

Aggiornamenti recenti sulla crescita futura

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

May 03

Recent updates

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Aug 17

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Jun 14

Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals

May 07

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

May 03

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Feb 10

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

Sep 23

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Apr 06

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Feb 19

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Feb 17

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Feb 10

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Nov 24

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Oct 12

Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?

Dec 17

Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?

Oct 26

Previsioni di crescita degli utili e dei ricavi

NSEI:ROSSARI - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	28,895	2,388	1,624	2,222	3
3/31/2026	24,403	1,871	1,080	2,015	4
3/31/2025	20,636	1,496	586	2,355	4
9/30/2024	19,245	1,388	17	1,162	N/A
6/30/2024	19,096	1,364	N/A	N/A	N/A
3/31/2024	18,306	1,307	-880	433	N/A
12/31/2023	17,643	1,255	N/A	N/A	N/A
9/30/2023	16,898	1,168	-341	631	N/A
6/30/2023	16,318	1,078	N/A	N/A	N/A
3/31/2023	16,559	1,073	1,187	1,516	N/A
12/31/2022	16,883	1,027	N/A	N/A	N/A
9/30/2022	17,275	995	729	990	N/A
6/30/2022	16,866	1,018	N/A	N/A	N/A
3/31/2022	14,830	977	-89	294	N/A
12/31/2021	12,623	957	N/A	N/A	N/A
9/30/2021	10,438	948	-342	129	N/A
6/30/2021	8,310	892	N/A	N/A	N/A
3/31/2021	7,093	802	-103	478	N/A
12/31/2020	6,507	729	N/A	N/A	N/A
9/30/2020	6,031	695	198	1,045	N/A
6/30/2020	5,818	666	N/A	N/A	N/A
3/31/2020	6,001	653	-191	568	N/A
3/31/2019	5,162	457	272	712	N/A
3/31/2018	2,922	254	N/A	254	N/A
3/31/2017	2,350	143	N/A	67	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di ROSSARI ( 22.3% all'anno) è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Si prevede che gli utili di ROSSARI ( 22.3% all'anno) cresceranno più rapidamente del mercato Indian ( 18% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ROSSARI cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ROSSARI ( 16.6% all'anno) crescerà più rapidamente del mercato Indian ( 10.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ROSSARI ( 16.6% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di ROSSARI sarà basso tra 3 anni ( 15.4 %).

Rossari Biotech Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 7.6% to ₹951

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

Price target increased by 9.0% to ₹852

Price target decreased by 8.4% to ₹782

Consensus revenue estimates fall by 13%

Price target decreased by 9.2% to ₹986

Recent updates

Now 22% undervalued after recent price drop

Rossari Biotech Limited Appoints Gurudas Aras as an Additional Director Designated as Non- Executive Independent Director

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited to Report Q2, 2025 Results on Oct 19, 2024

Price target increased by 7.6% to ₹951

Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March, 2024

Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All

Upcoming dividend of ₹0.50 per share

Rossari Biotech Limited, Annual General Meeting, Aug 23, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Rossari Biotech Limited to Report Q1, 2025 Results on Jul 20, 2024

Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?

Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals

Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report

Full year 2024 earnings: EPS misses analyst expectations

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Now 20% undervalued

Price target increased by 9.0% to ₹852

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Price target decreased by 8.4% to ₹782

Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)

Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023

First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)

Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Investor sentiment improves as stock rises 16%

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Upcoming dividend of ₹0.50 per share at 0.1% yield

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Consensus revenue estimates fall by 13%

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Price target decreased by 9.2% to ₹986

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)

Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)

Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022

Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Upcoming dividend of ₹0.50 per share

Full year 2022 earnings: EPS misses analyst expectations

Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022

Price target decreased to ₹1,252

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to ₹1,330

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Insider recently sold ₹2.1m worth of stock

Price target increased to ₹1,270

First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)

Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals Business

Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.

Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)

Investor sentiment improved over the past week

Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investors